Milrinone Market

The Milrinone market is expected to grow at a CAGR of 5.7% between 2025 and 2035, driven by its increasing use in the treatment of heart failure, particularly acute decompensated heart failure (ADHF). Milrinone, a phosphodiesterase-3 inhibitor, is commonly used as an inotropic agent to improve heart function by increasing the contractility of the heart and reducing pulmonary congestion in patients with heart failure. As the global incidence of heart failure rises, driven by aging populations and increasing cardiovascular disease, the demand for Milrinone, both as an active ingredient and in finished dosage forms, is expected to rise.

Geographically, North America holds the largest share of the Milrinone market, supported by advanced healthcare systems and high rates of heart failure diagnoses. Europe follows closely, where growing adoption of Milrinone in critical care units and the rising number of heart failure patients are expected to drive demand. The Asia-Pacific region is experiencing significant growth, especially in countries like China and India, where the increasing prevalence of heart failure and improving healthcare access are contributing to the demand for heart failure therapies. Latin America and the Middle East, and Africa are also contributing to market growth, with expanding access to essential cardiovascular treatments and an increase in healthcare infrastructure.

The market report is evolving by benefiting from ongoing research into new applications for Milrinone, including its potential use in combination therapies and as part of intensive care protocols for heart failure management. Additionally, as more healthcare systems improve their cardiovascular care, demand for Milrinone is expected to increase.